RxSight/$RXST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Ticker
$RXST
Sector
Primary listing
Employees
498
Headquarters
Website
RxSight Metrics
BasicAdvanced
$347M
-
-$0.80
1.15
-
Price and volume
Market cap
$347M
Beta
1.15
52-week high
$53.16
52-week low
$6.32
Average daily volume
826K
Financial strength
Current ratio
13.927
Quick ratio
12.537
Long term debt to equity
3.818
Total debt to equity
4.214
Interest coverage (TTM)
-2,025.33%
Profitability
EBITDA (TTM)
-39.323
Gross margin (TTM)
73.12%
Net profit margin (TTM)
-21.93%
Operating margin (TTM)
-28.92%
Effective tax rate (TTM)
-0.23%
Revenue per employee (TTM)
$300,000
Management effectiveness
Return on assets (TTM)
-8.65%
Return on equity (TTM)
-11.66%
Valuation
Price to revenue (TTM)
2.327
Price to book
1.25
Price to tangible book (TTM)
1.25
Price to free cash flow (TTM)
-16.39
Free cash flow yield (TTM)
-6.10%
Free cash flow per share (TTM)
-0.517
Growth
Revenue change (TTM)
27.68%
Earnings per share change (TTM)
-20.15%
3-year revenue growth (CAGR)
62.12%
3-year earnings per share growth (CAGR)
-31.40%
What the Analysts think about RxSight
Analyst ratings (Buy, Hold, Sell) for RxSight stock.
Bulls say / Bears say
The installed base of Light Delivery Devices expanded 34% YoY to 1,084 units as of June 30, 2025, laying the groundwork for future consumable LAL revenue growth (Nasdaq).
RxSight’s gross margin improved to 74.9% in Q2 2025 from 69.5% in Q2 2024, driven by a favorable product mix shift toward higher-margin Light Adjustable Lens sales (Nasdaq).
During Q2 2025, RxSight launched its Light Adjustable Lens system in South Korea and Singapore and received FDA approval to expand the lens dioptric range, diversifying its market presence and regulatory footprint (TipRanks).
Full-year 2025 revenue guidance was cut dramatically to $120 million–$130 million from $160 million–$175 million, implying a 7%–14% YoY decline and underscoring significant headwinds in LDD adoption (Investopedia).
Second-quarter 2025 revenue of $33.6 million represented an 11% sequential drop from Q1 2025’s $37.9 million, signaling waning near-term demand for both LALs and LDDs (Nasdaq).
Light Delivery Device unit sales plunged 49% YoY to just 40 units in Q2 2025, highlighting execution challenges in expanding the device install base critical for recurring LAL consumable revenue (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2025.
RxSight Financial Performance
Revenues and expenses
RxSight Earnings Performance
Company profitability
RxSight News
AllArticlesVideos
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight
Business Wire4 weeks ago
Deadline Soon: RxSight, Inc. (RXST) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Business Wire4 weeks ago
EXTENDED CLASS PERIOD: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against RxSight, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RxSight stock?
RxSight (RXST) has a market cap of $347M as of October 18, 2025.
What is the P/E ratio for RxSight stock?
The price to earnings (P/E) ratio for RxSight (RXST) stock is 0 as of October 18, 2025.
Does RxSight stock pay dividends?
No, RxSight (RXST) stock does not pay dividends to its shareholders as of October 18, 2025.
When is the next RxSight dividend payment date?
RxSight (RXST) stock does not pay dividends to its shareholders.
What is the beta indicator for RxSight?
RxSight (RXST) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.